Bezafibrate Treatment of Primary Biliary Cirrhosis Following Incomplete Response to Ursodeoxycholic Acid
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND GOALS: Ursodeoxycholic acid (UDCA) is the only current pharmacologic treatment for primary biliary cirrhosis (PBC). However, some patients show persistent liver biochemical abnormalities even after 6 to 12 months treatment. Bezafibrate retard is a commonly used medication for hyperlipidemia. In Japanese studies, it was found to lower liver enzyme levels, apparently through its action on multiple drug resistance gene 3, a transport element of the ATP-dependent bile secretion system, and on peroxisome proliferator-activated receptor-alpha. The aim of this study was to evaluate the effect of adding bezafibrate to the treatment regimen in patients with PBC and a partial response to UDCA. STUDY: The study group included 8 White patients, 7 women and 1 man, aged 52 to 76 years with PBC who had been treated at our Liver Institute with UDCA (900 mg/d to 1500 mg/d) for 2 to 11 years (mean, 5.7 y) with only a partial response (19% to 56% reduction in alkaline phosphatase level). Bezafibrate (400 mg/d) was added to UDCA and the patients were followed for 4 to 12 months. RESULTS: Alkaline phosphatase levels (normal range, 35 to 104 U/L) decreased in all patients, from 140 to 360 U/L (mean, 201.2) to 68 to 158 U/L (mean, 98.4), and normalized in 6 patients. In addition, levels of gamma-glutamyl transferase (normal range, 6 to 42 U/L) decreased from 70 to 192 U/L (mean, 130) to 41 to 122 U/L (mean, 71.8). These findings were maintained throughout follow-up. CONCLUSIONS: Combination therapy with bezafibrate and UDCA improves the biochemical profile of patients with PBC who respond only partially to UDCA. A larger controlled study is needed to evaluate the clinical implications of these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756 · cited 1×
“However, there remain about 40% of patients who show only a suboptimal response and require further treatment.(9) According to reports from Japan, bezafibrate successfully lowers biliary liver enzymes.”
BackgroundPoupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Bezafibrate treatment: a new medical approach for PBC patients?
Kanda, T., Yokosuka, O., Imazeki, F., & Saisho, H. (2003) · Journal of Gastroenterology · doi:10.1007/s00535-002-1102-7 · Cited by 129
Long‐term fibrate treatment for PBC
Nakamuta, M., Enjoji, M., Kotoh, K., Shimohashi, N., & Tanabe, Y. (2005) · Journal of Gastroenterology · doi:10.1007/s00535-004-1583-7 · Cited by 26 · cited 1×
“In 2 of these studies, including 45 patients, bezafibrate also decreased serum IgM levels; however, in no case was there a change in AMA titer.(16,19) One of the studies included 17 patients with PBC, of whom 11 had been treated with UDCA alone for an average of 19 months before the start of combination therapy with b…”
Cited by
Bile acid transporters and regulatory nuclear receptors in the liver and beyond
Halilbasic, E., Claudel, T., & Trauner, M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.08.002 · Cited by 393
Ghonem, N. S., Assis, D. N., & Boyer, J. L. (2015) · Hepatology · doi:10.1002/hep.27744 · Cited by 317
Levy, C., Peter, J. A., Nelson, D. R., Keach, J., Petz, J., Cabrera, R., Clark, V., Firpi, R. J., Morelli, G., Soldevila-Pico, C., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04512.x · Cited by 186
Reig, A., Sesé, P., & Parés, A. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.287 · Cited by 115
Lens, S., Leoz, M., Nazal, L., Bruguera, M., & Parés, A. (2014) · Liver International · doi:10.1111/liv.12290 · Cited by 107
Metadata
- Authors
- Hazzan, R., & Tur-Kaspa, R.
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2010-05
- Volume
- 44
- Issue
- 5
- Pages
- 371-373
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W2028940189
- Cited by
- 64
- References
- 5
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bezafibrate Treatment of Primary Biliary Cirrhosis Following Incomplete Response to Ursodeoxycholic Acid. https://app.cochat.ai/papers/10.1097/mcg.0b013e3181c115b3
- The paper
- Hazzan, R., & Tur-Kaspa, R. (2010). Bezafibrate Treatment of Primary Biliary Cirrhosis Following Incomplete Response to Ursodeoxycholic Acid. Journal of Clinical Gastroenterology. https://doi.org/10.1097/mcg.0b013e3181c115b3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.